Melanoma & Skin Cancer

New treatment approaches that improve overall survival for patients with late-stage melanoma spotlighted

Dr. Wolchok from Memorial Sloan-Kettering Cancer Center Describes the Immunotherapy Ipilimumab

The combination of the MEK inhibitor GSK212 and the oral BRAF inhibitor GSK436 resulted in anti-tumor activity in patients with advanced melanoma

Dr. Axel Hoos from Bristol Myers-Squib on the Patients That Respond to Ipilimumab

Dr. Paul Chapman from Memorial Sloan-Kettering Cancer Center Describes the Side Effects of Vemurafenib

Tim Turnham the Executive Director of the Melanoma Research Foundation Discusses Melanoma Treatment Advances

Dana Monroe from San Francisco Oncology Associates Discusses Ipilimumab's Side Effects

An experimental melanoma vaccine gp100 peptide vaccine in combination with IL2 may shrink tumors and prevent the progression of late-stage melanoma

Melanoma is now being treated with drugs and new treatment regimes that have shown great promise

Each year the National Comprehensive Cancer Network (NCCN) presents the latest updates to its Clinical Practice Guidelines in Oncology, as well as the latest cancer therapies by key opinion leaders.

Vemurafenib works by selectively targeting and inhibiting a mutated form of the BRAF protein found in about half of all cases of melanoma

The FDA recently approved the immunotherapy ipilimumab (Yervoy) as a second-line treatment for patients with metastatic melanoma

As immunotherapy options grow, oncologists will need new frameworks of reference for evaluating whether patients are benefiting from the treatments

Researchers at SFOA have examined the challenges ipilimumab's unique side-effect profile presents to oncology professionals

The ambitious effort to portray the cancer journey of one fictional patient marks an intersection of medicine and entertainment that has attracted widespread attention

A look at cancer centers, resources, clinical trials, CME and other offerings from across the web

A biomarker test for DNA methylation identified 22 gene sites able to differentiate between melanoma and nonmelanoma lesions

Bristol-Myers Squibb plans to start rolling out its newly approved melanoma drug ipilimumab (Yervoy) in the next several weeks

The FDA has approved the novel drug ipilimumab for the treatment of patients with metastatic melanoma

Cancer researchers and patient advocates are hailing the FDA's approval of Yervoy (ipilimumab)

James P. Allison has never hesitated to buck the system

Andrew L. Pecora, M.D., F.A.C.P., C.P.E. Chief Innovations Officer, Professor and Vice President of Cancer Services at John Theurer Cancer Center, on his personal involvement in research.

Useful Online Resources and Clinical Trials for Melanoma

The shortage, which began in 2009, accelerated in 2010, and has shown no signs of abatement so far in 2011, according to Erin R. Fox, PharmD, manager of the Drug Information Service at University of Utah Health Care

Various immunotherapeutic strategies to treat advanced melanoma have been under investigation for more than a decade